Core Insights - Diamond Hill Capital's "Select Fund" underperformed the Russell 3000 Index in Q3 2025, returning 4.98% compared to the index's 8% gain [1] - The fund initiated four new positions in Q3, including Berkshire Hathaway Inc., indicating a focus on companies with long-term growth potential despite market trends [3] Company Highlights - Berkshire Hathaway Inc. (NYSE:BRK-B) had a one-month return of -3.51% and a 52-week gain of 6.12%, closing at $478.52 per share with a market capitalization of $1.03 trillion on October 30, 2025 [2] - The number of hedge funds holding Berkshire Hathaway increased from 125 to 133 in the second quarter, reflecting its popularity among institutional investors [4] - Despite its strong franchise, some analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk compared to Berkshire Hathaway [4]

Core Insights - Diamond Hill Capital's "Select Fund" underperformed the Russell 3000 Index in Q3 2025, returning 4.98% compared to the index's 8% gain [1] - The fund initiated four new positions in Q3, including Adobe Inc. (NASDAQ:ADBE), indicating a belief in the long-term growth potential of selected companies despite market trends [3] Company Performance - Adobe Inc. reported record revenue of $5.99 billion in Q3 2025, reflecting a 10% year-over-year growth [4] - The stock of Adobe Inc. closed at $337.86 on October 29, 2025, with a market capitalization of $141.428 billion [2] Stock Analysis - Adobe Inc. experienced a one-month return of -2.56% and a significant decline of 30.02% over the past 52 weeks [2] - The company is ranked 13th among the 30 Most Popular Stocks Among Hedge Funds, with 104 hedge fund portfolios holding its stock at the end of Q2 2025, down from 111 in the previous quarter [4]

Core Insights - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its third-quarter 2025 earnings report, scheduled for November 4, 2025, with revenue estimates at $2.41 billion and earnings per share (EPS) at $1.62 [1][5] Group 1: Revenue Sources - The company generates most of its revenue from a diverse portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional income from non-pharmaceutical categories such as nutritional products and precision animal health services [2] - Revenue from the U.S. segment is projected to increase, primarily due to rising sales of companion animal products, with estimates at $1.34 billion according to Zacks Consensus and $1.38 billion based on internal models [3] - The International segment is also expected to see revenue growth, driven by higher sales of companion animal products, with estimates of $1.04 billion from Zacks and $1.03 billion from internal models [4] Group 2: Product Performance - Companion animal products, particularly Simparica Trio, Apoquel, and Cytopoint, are expected to significantly contribute to revenue growth in both U.S. and International segments [5][7] - However, sales of monoclonal antibody products for osteoarthritis, Librela and Solensia, are likely to decline in the U.S. due to concerns over side effects [8] - The FDA's recent approval of a new indication for Simparica Trio is expected to further enhance sales by preventing flea tapeworm infections [9] Group 3: Livestock Products - Livestock product sales in both U.S. and International segments are anticipated to decline due to the divestiture of certain product lines, including medicated feed additives and water-soluble products [10] Group 4: Earnings Surprise History - Zoetis has a strong earnings surprise history, having surpassed estimates in the last four quarters with an average surprise of 6.19%, including an 8.64% surprise in the most recent quarter [11][12] Group 5: Earnings Prediction - The company's earnings model indicates a likely earnings beat, supported by a positive Earnings ESP of +0.32% and a Zacks Rank of 3 [13]

Core Insights - Portela has become the first monoclonal antibody (mAb) therapy approved for a three-month dosing interval to alleviate pain associated with osteoarthritis (OA) in cats [1] Company Summary - The approval of Portela marks a significant advancement in veterinary medicine, particularly in the treatment of OA in felines [1] Industry Summary - This development highlights the growing trend in the animal health industry towards long-acting therapies, which can improve compliance and outcomes for pet owners and their animals [1]

Core Viewpoint - Zoetis Inc. has appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025, enhancing its leadership with her extensive experience in technology and digital health [1] Company Summary - Stephanie Tilenius is a serial entrepreneur with a background in founding healthcare companies, including a recent venture in the longevity AI sector [1] - She previously founded Vida Health, Inc., which is recognized as a leading B2B company in the healthcare space [1]

Core Insights - Zoetis Inc. is currently in the final 18th phase of the Adhishthana cycle, with a poor triad structure indicating a negative outlook for the stock [1][6] - UBS has recently lowered its price targets for Zoetis, reinforcing the expectation that the stock may remain in a slump until June 2026 [1][6] Group 1: Adhishthana Cycle Analysis - The behavior of Phase 18 is influenced by Phases 14, 15, and 16, known as the Guna Triads, which must exhibit Satoguna for a bullish trend to develop [2] - Zoetis entered its triads in February 2023, but there has been no sustained bullish momentum, indicating that a Nirvana move is unlikely in Phase 18 [4] - Since entering the final phase in December 2024, Zoetis has been in a sluggish, range-bound trend, consistent with Adhishthana principles [5] Group 2: Investor Outlook - The weak triads and diminished institutional confidence suggest a muted outlook for Zoetis, with expectations of continued underperformance through mid-2026 [6] - Investors looking to build long positions are advised to wait for a cycle reset, as any short-lived rallies are unlikely to be sustainable [7] - Options traders may find opportunities in range-bound credit spreads due to the expected sideways movement of the stock [7]

Core Insights - Zoetis (ZTS) has a strong history of beating earnings estimates and is well-positioned for future earnings growth [1][5] - The company has surpassed earnings estimates by an average of 7.18% over the last two quarters [1][5] - The upcoming earnings report is expected on November 4, 2025 [8] Earnings Performance - For the last reported quarter, Zoetis achieved earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 per share by 8.64% [2] - In the previous quarter, the company reported earnings of $1.48 per share against an expectation of $1.4 per share, resulting in a surprise of 5.71% [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The company currently has an Earnings ESP of +0.41%, indicating a positive outlook from analysts regarding its earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [8][6]

Core Insights - Zoetis (ZTS) received a positive opinion from the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) for its investigational monoclonal antibody therapy, Lenivia, aimed at relieving osteoarthritis pain in dogs [1][5][6] - The final decision from the European regulatory body is expected in Q4 2025, with a potential commercial launch in 2026 [2][9] - Lenivia is designed to provide pain relief for up to three months with a single injection, targeting nerve growth factor (NGF) [3][8] Company Developments - The approval of Lenivia would enhance Zoetis' leadership in the animal health sector and expand its innovative portfolio in companion animal therapeutics [6] - Lenivia will complement the existing product Librela, providing veterinarians and pet owners with both monthly and quarterly treatment options for managing osteoarthritis pain in dogs [5][8] - The company has also received a positive opinion for another monoclonal antibody therapy, Portela, for managing osteoarthritis pain in cats, which is expected to launch in 2026 if approved [9][11] Market Context - Osteoarthritis is a common condition affecting nearly 40% of dogs, leading to significant pain and reduced mobility [7] - The introduction of Lenivia and Portela could deepen Zoetis' penetration into the growing canine and feline osteoarthritis market, improving treatment adherence due to less frequent dosing schedules [11]

Group 1 - The article emphasizes the importance of identifying undervalued stocks with a focus on balancing risk and reward, suggesting that simplicity often leads to the best investment ideas [1] - It advocates for a contrarian investment approach, indicating that taking positions against prevailing market trends can yield better results [1] Group 2 - There are no specific companies or stocks mentioned in the article, and the author has no current positions or plans to initiate any positions in the near future [2] - The article does not provide any investment recommendations or advice, highlighting that past performance does not guarantee future results [3]

Core Insights - IDEXX Laboratories, Inc. is recognized as one of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years, specializing in animal health diagnostics and related services [1] - The company reported Q2 earnings for August 2025, with revenue of $1.11 billion, marking a 10.6% year-over-year increase, and earnings per share of $3.63, exceeding market expectations [2] - The launch of the inVue Dx analyzer has been a significant growth driver, with 2,400 units installed in Q2, leading to an upward revision of the full-year installation target to 5,500 units [3] - IDEXX shares have delivered a 97% return over the past three years, outperforming competitors like Zoetis and the broader market, with projected earnings per share for 2025 between $12.40 and $12.76 [4]